Best Stock on the Market

Call Spread on BIIB on 1/2/2014

Bullish Flag on BIIBBiogen Idec (BIIB) discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally.

Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability.

The company’s products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company’s Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. 

Shares have formed a bullish "flag" and higher share prices are expected for this stock.

52-Week Trading Range: $139.72 - $298.82

Last Trade: $281.27

Trade

  • Buy 1 January $280.00 Call at $7.50
  • Sell 1 January $285.00 Call at $5.20
  • For a net debit of $2.30

Profit/Loss Analysis

  • Breakeven at $282.30
  • Maximum profit is $270.00 at strike of $285.00
  • Maximum loss is ($230.00) at strike of $280.00

Closing Summary

  • Sold 1 January $280.00 Call at $8.50
  • Bought 1 January $285.00 Call at $5.60

Position closed on 1/8/2014 at price of $2.90 with a 26.09% gain in 5 days.

Updates

1/8/2014 11:46:43 AM

We are taking profits on BIIB Call Sread tade.

Back to Portfolio